Trexquant Investment LP Has $4.71 Million Position in LivaNova PLC (NASDAQ:LIVN)

Trexquant Investment LP boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 139.7% in the fourth quarter, Holdings Channel reports. The firm owned 101,653 shares of the company’s stock after acquiring an additional 59,241 shares during the period. Trexquant Investment LP’s holdings in LivaNova were worth $4,708,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Cerity Partners LLC bought a new stake in LivaNova during the third quarter valued at about $573,000. FMR LLC boosted its stake in LivaNova by 68.0% during the 3rd quarter. FMR LLC now owns 31,466 shares of the company’s stock valued at $1,653,000 after purchasing an additional 12,735 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in LivaNova by 92.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,740 shares of the company’s stock valued at $6,449,000 after buying an additional 58,807 shares during the last quarter. Captrust Financial Advisors bought a new position in LivaNova in the 3rd quarter worth approximately $217,000. Finally, Verition Fund Management LLC lifted its holdings in shares of LivaNova by 47.4% during the third quarter. Verition Fund Management LLC now owns 11,542 shares of the company’s stock worth $606,000 after buying an additional 3,710 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

Shares of LIVN stock opened at $35.95 on Friday. The stock’s fifty day moving average is $43.47 and its 200-day moving average is $48.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 52 week low of $35.24 and a 52 week high of $64.48. The stock has a market capitalization of $1.95 billion, a PE ratio of 85.60 and a beta of 0.90.

Analyst Ratings Changes

Several brokerages have recently issued reports on LIVN. The Goldman Sachs Group lowered their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Monday, March 17th. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Finally, Stifel Nicolaus decreased their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Buy” and a consensus price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.